Our diverse panel of speakers from across the world will share their opinions, insights and expertise at this not to be missed event as we accelerate towards realising synthetic biology's true potential.
More speakers to be annouced soon.
Dr Irina Haivas
Irina Haivas is a Principal. Based in London, she works on sourcing and due diligence of global investment opportunities.
Irina focuses on machine intelligence-enabled businesses, next-generation biology, robotics and other frontier technologies. She also focuses on companies in healthcare.
Before joining Atomico, Irina was a growth and PE investor at GHO Capital Partners, where she focused on the intersection of life sciences, health and technology, including AI/ML and enterprise software. Before that, Irina was part of the leadership team of Bain & Co. in Europe and the U.S., where she worked directly with pharmaceutical and medical technology companies on scale-ups, product development and commercialisation, business model innovation, M&A, and organisational development. While at Bain she seconded for a year in an operational role at Medtronic, one of the world’s largest medical device companies.
Irina is a former surgeon, having studied medicine at Freiburg University in Germany and Iasi Medical University in Romania. She was a surgical fellow at Harvard Medical School before completing an MSc (Dist) in International Health Policy at London School of Economics.
Irina speaks Romanian, English, advanced German, and conversational French.
Dr Jason Kelly
Co-Founder and CEO, Gingko BioWorks
Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company that genetically engineers "made-to-order" cells for customers in the chemical, pharmaceutical, food, and energy industries.
The company engineers these cells in their 100,000 sqft automated genetic engineering foundry and has partnerships with companies including ADM, Cargill, and Ajinomoto as well as top 5 beverage, petrochemical, and electronics companies. Ginkgo recently announced a $100M joint venture with Bayer to develop microbes to make food crops self-fertilizing and in 2017 Ginkgo was selected #7 on CNBC's Disruptor 50 List of fast-growing companies.
Jason has previously spoken at the World Economic Forum in Davos, the Allen & Co Sun Valley conference, and the US Library of Congress. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.
University of Oxford, UK
Professor Hagan Bayley
Professor of Chemical Biology , University of Oxford, UK
Hagan Bayley is Professor of Chemical Biology at the University of Oxford. Major interests of his laboratory are the development of engineered pores for stochastic sensing, the study of covalent chemistry at the single molecule level, ultra-rapid DNA sequencing and the fabrication of synthetic tissues.
He received his B.A. in chemistry from Oxford in 1974, while at Balliol College, and his Ph.D. in chemistry from Harvard University in 1979 in the laboratory of Jeremy Knowles. After postdoctoral work with Gobind Khorana at the Massachusetts Institute of Technology, he was on the faculty at Columbia University and the University of Oxford. From 1988 to 1996, he was at the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts, and from 1997 to 2003 at Texas A&M University in College Station.
In 2005, Professor Bayley founded Oxford Nanopore to exploit the potential of stochastic sensing technology. The company has developed the MinION portable DNA sequencer. In 2014, he founded OxSyBio to build synthetic tissues for regenerative medicine. He has been a recipient of the Royal Society’s Wolfson Research Merit Award and was the 2009 Chemistry World Entrepreneur of the Year. In 2011, Professor Bayley was elected a Fellow of the Royal Society. In 2012, he was awarded the Royal Society of Chemistry's Interdisciplinary Prize and in 2017, the Menelaus Medal of the Learned Society of Wales. In, 2018 Professor Bayley held the Kavli Chair at TU Delft.